ISSUE 78 I JANUARY 2019

gut

instinct

Could a recently discovered family of gut bacteria form the foundation for the first drugs using microbiome bacteria?

In association with

02/23/2024 22:24:00

01/07/2019 00:00:00

Go to article: Home | Gut Instinct Go to article: In this issue Go to article: TSS Company Insight Go to article: TSS AB Go to article: International Cannabis and Cannabinoid Institute (ICCI) Company Insight Go to article: International Cannabis and Cannabinoid Institute (ICCI)Go to article: Contents Go to article: Daiichi Jitsugyo Go to article: News Go to article: Scandinavian Health Ltd.Go to article: The Pharma Industry Briefing Go to article: Komtur Pharmaceuticals Go to article: Komtur Pharmaceuticals Company Insight Go to article: How will the UK’s relaxed cannabis regulations impact clinical practice?Go to article: Finnair Cargo Go to article: Finnair Cargo | Company Insight Go to article: Developing a new class of cancer combo drugs Go to article: Phoenix Company Insight Go to article: Phoenix Go to article: Antidepressants in the environment: combatting pharmaceutical pollution Go to article: AtoZ-CRO GmbH Go to article: AtoZ-CRO GmbH Company Insight Go to article: Christensella: the key to unlocking gut microbiome-based drug discovery?Go to article: CBDepot Go to article: CBDepot Company Insight Go to article: Going digital to improve clinical trial enrolment Go to article: BEA Go to article: Incretin combination therapy: a breakthrough for type 2 diabetes?Go to article: Alpex Go to article: Ebola in the DRC: vaccinating in a conflict zone Go to article: Hemp Industries Go to article: Unither Pharmaceuticals Go to article: Data overload: turning challenges into opportunities in clinical trials Go to article: Zenatek Go to article: Solving clinical research challenges: an IT perspective Go to article: Pfanstiehl Company Insight Go to article: Pfanstiehl Go to article: Events Go to article: In the next issue